These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 24003687)

  • 1. [Guidelines on biologic drugs for the treatment of children with juvenile idiopathic arthritis (JIA)].
    Bukovac LT; Vidović M; Lamot L; Perica M; Harjacek M;
    Reumatizam; 2013; 60(1):57-66. PubMed ID: 24003687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry.
    Schmeling H; Minden K; Foeldvari I; Ganser G; Hospach T; Horneff G
    Arthritis Rheumatol; 2014 Sep; 66(9):2580-9. PubMed ID: 24942886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and long-term retention of anti-tumour necrosis factor treatment in juvenile and adult patients with juvenile idiopathic arthritis: data from Reuma.pt.
    Mourão AF; Santos MJ; Melo Gomes JA; Martins FM; Mendonça SC; Oliveira Ramos F; Fernandes S; Salgado M; Guedes M; Carvalho S; Costa JA; Brito I; Duarte C; Furtado C; Lopes A; Rodrigues A; Sequeira G; Branco JC; Fonseca JE; Canhão H
    Rheumatology (Oxford); 2016 Apr; 55(4):697-703. PubMed ID: 26672905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biologics in juvenile idiopathic arthritis: a narrative review.
    Vanoni F; Minoia F; Malattia C
    Eur J Pediatr; 2017 Sep; 176(9):1147-1153. PubMed ID: 28725955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Juvenile idiopathic arthritis - what the clinician needs to know.
    Kahn PJ
    Bull Hosp Jt Dis (2013); 2013; 71(3):194-9. PubMed ID: 24151944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register.
    Otten MH; Anink J; Prince FH; Twilt M; Vastert SJ; ten Cate R; Hoppenreijs EP; Armbrust W; Gorter SL; van Pelt PA; Kamphuis SS; Dolman KM; Swart JF; van den Berg JM; Koopman-Keemink Y; van Rossum MA; Wulffraat NM; van Suijlekom-Smit LW
    Ann Rheum Dis; 2015 Jul; 74(7):1379-86. PubMed ID: 24641940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disease activity of idiopathic juvenile arthritis continues through adolescence despite the use of biologic therapies.
    Vidqvist KL; Malin M; Varjolahti-Lehtinen T; Korpela MM
    Rheumatology (Oxford); 2013 Nov; 52(11):1999-2003. PubMed ID: 23893666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of methotrexate in children with rheumatic diseases.
    Gutiérrez-Suárez R; Burgos-Vargas R
    Clin Exp Rheumatol; 2010; 28(5 Suppl 61):S122-7. PubMed ID: 21044445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of biologic treatments on growth in children with juvenile idiopathic arthritis.
    Uettwiller F; Perlbarg J; Pinto G; Bader-Meunier B; Mouy R; Compeyrot-Lacassagne S; Melki I; Wouters C; Prieur AM; Landais P; Polak M; Quartier P
    J Rheumatol; 2014 Jan; 41(1):128-35. PubMed ID: 24293576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parents' willingness to pay for biologic treatments in juvenile idiopathic arthritis.
    Burnett HF; Ungar WJ; Regier DA; Feldman BM; Miller FA
    Value Health; 2014 Dec; 17(8):830-7. PubMed ID: 25498778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment Withdrawal Following Remission in Juvenile Idiopathic Arthritis: A Systematic Review of the Literature.
    Halyabar O; Mehta J; Ringold S; Rumsey DG; Horton DB
    Paediatr Drugs; 2019 Dec; 21(6):469-492. PubMed ID: 31673960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term quality of life and functional outcome of patients with juvenile idiopathic arthritis in the biologic era: a longitudinal follow-up study in the Dutch Arthritis and Biologicals in Children Register.
    Anink J; Prince FH; Dijkstra M; Otten MH; Twilt M; ten Cate R; Gorter SL; Koopman-Keemink Y; van Rossum MA; Hoppenreijs EP; van Suijlekom-Smit LW
    Rheumatology (Oxford); 2015 Nov; 54(11):1964-9. PubMed ID: 26078219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel treatment options for juvenile idiopathic arthritis.
    Steigerwald KA; Ilowite NT
    Expert Rev Clin Pharmacol; 2015; 8(5):559-73. PubMed ID: 26294075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort.
    Guzman J; Oen K; Tucker LB; Huber AM; Shiff N; Boire G; Scuccimarri R; Berard R; Tse SM; Morishita K; Stringer E; Johnson N; Levy DM; Duffy KW; Cabral DA; Rosenberg AM; Larché M; Dancey P; Petty RE; Laxer RM; Silverman E; Miettunen P; Chetaille AL; Haddad E; Houghton K; Spiegel L; Turvey SE; Schmeling H; Lang B; Ellsworth J; Ramsey S; Bruns A; Campillo S; Benseler S; Chédeville G; Schneider R; Yeung R; Duffy CM;
    Ann Rheum Dis; 2015 Oct; 74(10):1854-60. PubMed ID: 24842571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment prescribing patterns in patients with juvenile idiopathic arthritis (JIA): Analysis from the UK Childhood Arthritis Prospective Study (CAPS).
    Davies R; Carrasco R; Foster HE; Baildam EM; Chieng SEA; Davidson JE; Ioannou Y; Wedderburn LR; Thomson W; Hyrich KL
    Semin Arthritis Rheum; 2016 Oct; 46(2):190-195. PubMed ID: 27422803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Etanercept (Enbrel) in the treatment of juvenile idiopathic arthritis.
    Berard RA; Laxer RM
    Expert Opin Biol Ther; 2013 Nov; 13(11):1623-30. PubMed ID: 24070010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Term Outcomes in Juvenile Idiopathic Arthritis: Eighteen Years of Follow-Up in the Population-Based Nordic Juvenile Idiopathic Arthritis Cohort.
    Glerup M; Rypdal V; Arnstad ED; Ekelund M; Peltoniemi S; Aalto K; Rygg M; Toftedal P; Nielsen S; Fasth A; Berntson L; Nordal E; Herlin T;
    Arthritis Care Res (Hoboken); 2020 Apr; 72(4):507-516. PubMed ID: 30762291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting Which Children with Juvenile Idiopathic Arthritis Will Not Attain Early Remission with Conventional Treatment: Results from the ReACCh-Out Cohort.
    Guzman J; Henrey A; Loughin T; Berard RA; Shiff NJ; Jurencak R; Huber AM; Oen K; Gerhold K; Feldman BM; Scuccimarri R; Houghton K; Chédeville G; Morishita K; Lang B; Dancey P; Rosenberg AM; Barsalou J; Bruns A; Watanabe Duffy K; Benseler S; Duffy CM; Tucker LB;
    J Rheumatol; 2019 Jun; 46(6):628-635. PubMed ID: 30647178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biologic treatment response among adults with juvenile idiopathic arthritis: results from the British Society for Rheumatology Biologics Register.
    McErlane F; Foster HE; Davies R; Lunt M; Watson KD; Symmons DP; Hyrich KL
    Rheumatology (Oxford); 2013 Oct; 52(10):1905-13. PubMed ID: 23873820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of biologic therapy across individual juvenile idiopathic arthritis subtypes: A systematic review.
    Davies R; Gaynor D; Hyrich KL; Pain CE
    Semin Arthritis Rheum; 2017 Apr; 46(5):584-593. PubMed ID: 27914689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.